Article Text

Airspace dimension assessment with nanoparticles as a proposed biomarker for emphysema
  1. H Laura Aaltonen1,2,3,
  2. Madeleine Petersson Sjögren4,5,
  3. Jonas K F Jakobsson4,5,
  4. Hanna Nicklasson1,
  5. Sandra Diaz1,6,
  6. Francisco Sánchez Montiel1,2,
  7. Sophia Zackrisson1,2,
  8. Veronica Ideböhn4,
  9. Gunnar Engström7,
  10. Jakob Löndahl4,5,
  11. Per Wollmer1,2
  1. 1 Department of Translational Medicine, Diagnostic Radiology, Lund University, Lund, Sweden
  2. 2 Department of Imaging and Functional Medicine, Skåne University Hospital, Malmö, Sweden
  3. 3 Department of Radiology, University of Washington, Seattle, Washington, USA
  4. 4 Department of Design Sciences, Lund University, Lund, Sweden
  5. 5 Lund University, NanoLund, Lund, Sweden
  6. 6 Department of Pediatric Radiology, Karolinska University Hospital, Stockholm, Sweden
  7. 7 Department of Clinical Sciences, Lund University, Malmö, Sweden
  1. Correspondence to Dr H Laura Aaltonen, Department of Translational Medicine, Diagnostic Radiology, Lund University, Lund, Sweden; laura.aaltonen{at}


Airspace dimension assessment with nanoparticles (AiDA) is a novel method to measure distal airspace radius non-invasively. In this study, AiDA radii were measured in 618 individuals from the population-based Swedish CArdiopulmonary BioImaging Study, SCAPIS. Subjects with emphysema detected by computed tomography were compared to non-emphysematous subjects. The 47 individuals with mainly mild-to-moderate visually detected emphysema had significantly larger AiDA radii, compared with non-emphysematous subjects (326±48 µm vs 291±36 µm); OR for emphysema per 10 µm: 1.22 (1.13–1.30, p<0.0001). Emphysema according to CT densitometry was similarly associated with larger radii compared with non-emphysematous CT examinations (316±41 µm vs 291 µm±26 µm); OR per 10 µm: 1.16 (1.08–1.24, p<0.0001). The results are in line with comparable studies. The results show that AiDA is a potential biomarker for emphysema in individuals in the general population.

  • emphysema
  • respiratory measurement
  • exhaled airway markers
  • imaging/CT MRI

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Chronic obstructive pulmonary disease (COPD) originates in the distal airspaces, causing chronic inflammation and irreversible airspace enlargement, emphysema. The emphysematous component of COPD can be diagnosed by CT, which may be poorly accessible, expensive and complicated by large interobserver variation in interpretation, especially at early stages of disease. Reduced diffusing capacity for carbon monoxide (D L,CO), in the presence of airflow obstruction, is indicative of emphysema, but the method is not specific.1

We have suggested a simple method, airspace dimension assessment (AiDA), to determine distal airspace radius based on inhalation of nanoparticles. Nanoparticles deposit in the distal airspaces by diffusion, the probability being dependent on residence time in the lung and distance to an airspace wall. Measurement of deposition related to time allows the mean airspace radius (r AiDA) to be calculated.2–5 In a proof-of-concept study, a preliminary version of the method differentiated emphysema patients from healthy controls.6

The aim of this study was to determine if r AiDA differs between persons with and without CT-verified emphysema in an unselected population. We expected persons with enlarged, emphysematous airspaces to have larger r AiDA compared with non-emphysematous individuals. Secondary and tertiary aims were to determine whether subjects with emphysema suggested by lung function parameters have larger r AiDA relative to non-emphysematous persons, and to investigate the role of comorbidities.


The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a national population-based study with 30 154 participants between 50 and 64 years of age. Our study was performed in a random sample of participants examined in Malmö, Sweden, between 2014 and 2016 (figure 1, online supplemental 1).

Supplemental material

Figure 1

Exclusion chart. *Within the municipality of Malmö, Sweden, there were 51 061 registered inhabitants in the target age group in 2015. During the study time period, 4716 randomly selected individuals from the population registry were contacted, of which 50% (2358) participated. Of these, 744 randomly selected subjects underwent the AiDA measurements, corresponding to 1.5% of the target age population within the municipality. Please see online supplemental 1 for successful measurement criteria. AiDA, Airspace dimension assessment with nanoparticles.

In AiDA measurements, the subjects inhaled 50 nm nanoparticles and held their breath for 5–10 s. Exhaled nanoparticles were measured from a sample at a volumetric lung depth of 1300 mL. The procedure was repeated six times. Particle recovery was calculated as the ratio between exhaled and inhaled concentration.3 An exponential decay curve was fitted to the recovery values obtained at different breath-hold times, and the half-life (t ½) was calculated. By solving the diffusion equation, rAiDA is obtained:

Embedded Image

where D is the diffusion coefficient given by the Stokes-Einstein equation.2

A chest CT was obtained and interpreted visually by one of four chest radiologists. A semiquantitative emphysema score with a maximum value of 18 was recorded (online supplemental 1). CT-derived total lung capacity by volumetric CT was calculated, and the percentage of voxels with a Hounsfield unit value below −950 (RV-950) was recorded. Emphysema was also defined quantitatively using two RV-950 percentage thresholds; >7% and >5%. Pulmonary function tests were performed according to American Thoracic Society and European Respiratory Society (ATS/ERS) standards.


Of the 744 subjects who underwent AiDA measurements, 618 were eligible for analysis (figure 1). The 47 persons with visually detected emphysema demonstrated an average emphysema score of 3.4±3.2, indicating mild-to-moderate disease. Most subjects had normal lung function, but some showed airflow obstruction. The r AiDA was approximately normally distributed (online supplemental 3).

Supplemental material

The persons with emphysema had a significantly larger r AiDA compared with non-emphysematous subjects (tables 1A, B). By visual CT interpretation, the mean difference was 35 µm (95% CI 21 to 50 µm, p<0.0001). Findings were similar for emphysema defined by CT densitometry; mean differences were 25 µm (95% CI 11 to 36 µm, p<0.0001) and 37 µm (95% CI 15 to 59 µm, p<0.0001) for the 5% and 7% thresholds, respectively.

Table 1A

Subject characteristics with and without visually detected emphysema

Table 1B

Subject characteristics with and without emphysema according to CT RV-950 cutoff >5%

Dividing the r AiDA into tertiles, we observed that with increasing radius, an increasing percentage of the subjects had emphysema and airflow obstruction. (online supplemental 4)

Supplemental material

Logistic regression analysis was conducted using several definitions of emphysema and airflow obstruction (table 2). The radius was associated with increased OR with little effect of adjustments. No comorbidities caused significant differences in r AiDA (online supplementals 1 and 2).

Supplemental material

Table 2

rAiDA logistic regression models; odds ratios (95% CIs) N=618


This is the first study where distal airspace radii have been determined by nanoparticles in subjects with emphysema. In a previous study, we showed nanoparticle recovery at a single breath-hold time to be different between healthy subjects and patients with moderate to severe COPD. The present study in a population-based sample extends the information to calculation of distal airspace radius, r AiDA, in subjects with mainly mild emphysema. Our results are in line with comparative methods7–9 (online supplemental 5).

Supplemental material

The small airways, <2 mm in diameter, have been suggested as the major site of early pathology in COPD. The repetitive toxic deposition stimulates an inflammatory response, repair and remodelling sequence, which later gives rise to a quantifiable airflow obstruction currently used as the diagnostic standard.10 There is a long clinically silent period, where the pathophysiological changes do not result in airflow obstruction, and therefore the early stages of COPD often remain undiagnosed.1 Also, spirometry alone will not differentiate between obstruction caused by airway narrowing and emphysema.

Due to their small size, nanoparticles traverse the distal airspaces and deposit there by diffusion. The r AiDA in healthy volunteers is relatively constant at lung depths between 1000 and 2500 mL.5 The r AiDA cannot be taken to represent any specific airway generation, but corresponds to a mean of airspaces distal to generation 15–17. This may not apply in diseased airspaces with altered flow; further studies are needed.5

AiDA has similarities with D L,CO, both being dependent on distribution of inhaled gas and diffusion within the airways. In contrast, AiDA is independent of transfer across the air-blood interface, haemoglobin concentration, recent smoking and altitude. The instrument is potentially simpler, as no compressed gases are needed. Compared with CT, the AiDA test is potentially easier and cheaper to administer. AiDA entails neither radiation nor an image that needs interpretation.

The AiDA measurements cause a low exposure to nanoparticles. The subjects were exposed to 0.05% of daily mass and 0.60% of daily particle number exposure in a comparatively clean urban setting.11

The study has several limitations. AiDA is a new technology, and we rely on a prototype of the apparatus. The proportion of measurements not fulfilling the technical criteria was high (online supplemental 1). This was mainly caused by the fact that at the beginning of the experiment, the particle concentration in the reservoir, and therefore, the inspired gas, was not uniform, resulting in several insufficient measurements. The subjects without emphysema in this study did not necessarily have normal lungs—a number of subjects had airflow obstruction. Due to the low number of subjects in the population with emphysema, the findings were not further analysed in subgroups according to disease severity, phenotype or presence of bullae. As emphysema and bronchial abnormalities frequently coincide in COPD, it is difficult to examine each phenotype on its own. Further studies on persons with predominantly airway involvement versus parenchymal disease phenotype are warranted, as well as studies to visualise where exactly the particles deposit.

We suggest AiDA is a potential biomarker for emphysema.1 To validate the method, however, a diagnostic accuracy study in target populations should be conducted, and sensitivity and specificity calculated.

Ethics statements


The authors would like to acknowledge Haris Zilic from the Department of imaging and physiology, Skåne University Hospital, Malmö, Sweden, for conducting the AiDA measurements.


Supplementary materials


  • Contributors PW, JL, GE, LHA and JJ participated in the experimental design. LHA, JJ, MPS, VI, FSM and SD participated in the data collection. All authors participated in the data analysis and interpretation. LHA prepared the first draft of the manuscript. All authors revised and approved the final version to be published. All authors are accountable for all aspects of the work.

  • Funding This work was supported by The Swedish Heart and Lung Foundation (grant number not applicable), Knut and Alice Wallenberg Foundation (grant number not applicable), The Swedish Research Council (project 2011-3560); FORTE (grant number not applicable); the Crafoord foundation (grant number not applicable); the Swedish Governmental Agency for Innovation Systems/VINNOVA (grant number not applicable); the ERA-NET project EuroNanoMed2 (grant number not applicable); Governmental funding of clinical research within the National Health Services (grant number not applicable), Skåne region (grant number not applicable). The SCAPIS project has received additional material and equipment support from University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institutet and Karolinska University Hospital, Linköping University and University Hospital, Lund University and Skåne University Hospital, Umeå University and University Hospital, Uppsala University and University Hospital.

  • Competing interests PW and JL have a patent issued for the device used in the measurements. PW reports personal fees from AstraZeneca and Chiesi Pharma, outside the submitted work, SZ reports grants from Allmänna sjukhuset i Malmös stiftelse för bekämpande av cancer (Translation: Malmö general hospital’s foundation for defeating cancer), and grants from Stiftelsen för cancerforskning vid onkologiska kliniken vid Universitetssjukhuset Malmö (Translation: Foundation for cancer research within the department of oncology in Malmö University Hospital) outside the submitted work.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Airwaves
    The Triumvirate